Previous 10 | Next 10 |
Regulus Therapeutics press release (NASDAQ:RGLS): Q4 GAAP EPS of -$0.07. As of December 31, 2021, Regulus had $60.4M in cash and cash equivalents. For further details see: Regulus Therapeutics GAAP EPS of -$0.07
Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates -Successfully completed Pre-IND meeting with FDA for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program- - On track to submit IND and Initiate Phase 1 study in second...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Regulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , March 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the...
Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome --Final data and potential for $25m milestone anticipated in H1 2023-- PR Newswire SAN DIEGO , Feb. 24, 2022 /PRNewswire/ -- Regulus Therap...
Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference PR Newswire SAN DIEGO , Feb. 10, 2022 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and developm...
Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429 Company remains on track to submit IND and initiate Phase 1 study in second quarter 2022 Company to include evaluation of treatment impact on slowing cystic kidney expansion PR ...
Regulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development PR Newswire SAN DIEGO , Dec. 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and deve...
Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit PR Newswire SAN DIEGO...
Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity PR Newswire SAN DIEGO , Nov. 30, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development ...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...